Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19017356 | MUTANTS OF RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEINS | January 2025 | May 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18955940 | PREPARATION METHOD AND APPLICATION OF NANOBODY TARGETING DENGUE VIRUS NS1 PROTEIN | November 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18903289 | METHOD FOR CONSTRUCTING gE PROTEIN-DELETED PSEUDORABIES VIRUS STRAIN USING ADENINE BASE EDITOR AND USE THEREOF | October 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18801895 | ESTABLISHMENT AND SUSPENSION ACCLIMATION OF CRFK ADHERENT CELL LINE, AND ITS APPLICATION | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 17929256 | CAPSID-MODIFIED RAAV VECTOR COMPOSITIONS AND METHODS THEREFOR | September 2022 | March 2025 | Allow | 30 | 1 | 0 | No | No |
| 17750241 | NOVEL DUAL HELPER PLASMID | May 2022 | February 2025 | Allow | 33 | 1 | 0 | No | No |
| 17705092 | ASSAY FOR JC VIRUS ANTIBODIES | March 2022 | September 2024 | Allow | 30 | 1 | 0 | No | No |
| 17509798 | ADENOVIRUS LIBRARY AND METHODS | October 2021 | March 2025 | Allow | 40 | 1 | 0 | No | No |
| 17442739 | IMMUNOCHROMATOGRAPHIC ASSAY METHOD AND TEST STRIP FOR USE IN SAID METHOD | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17471105 | Systems and method for viral detection | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17389371 | VIRUS LYSIS AND NUCLEIC ACID PRESERVATION SOLUTION | July 2021 | December 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17423010 | ENHANCED CELL BASED SCREENING PLATFORM FOR ANTI-HBV THERAPEUTICS | July 2021 | May 2025 | Allow | 46 | 1 | 0 | No | No |
| 17420608 | SAMRNA VACCINE AND PREPARATION METHOD THEREFOR | July 2021 | March 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17418617 | MONOCLONAL ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF THAT BINDS TO THE L PROTEIN OF THE HUMAN PARAINFLUENZA VIRUS (PIV); METHOD AND KIT FOR DETECTING PIV | June 2021 | September 2024 | Allow | 38 | 0 | 0 | No | No |
| 17418608 | MONOCLONAL ANTIBODIES SPECIFIC FOR THE PB2 ANTIGEN OF THE HUMAN INFLUENZA A VIRUS (FLU), NUCLEOTIDE SEQUENCES, METHOD AND DIAGNOSTIC KIT FOR FLU INFECTION | June 2021 | July 2024 | Allow | 37 | 0 | 0 | No | No |
| 17347075 | Genetically Modified Cell Line for Production of Marek's Disease Virus Vaccine and Methods of Making and Using the Same | June 2021 | June 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17298106 | SAMPLE PRETREATMENT METHOD FOR VIRUS DETECTION | May 2021 | November 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17289297 | A NOVEL DNA VACCINE AGAINST CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS (CCHFV) | April 2021 | December 2024 | Allow | 44 | 2 | 0 | No | No |
| 17288006 | ONCOLYTIC VIRUS EXPRESSING PD-1 BINDING PROTEIN AND APPLICATION OF ONCOLYTIC VIRUS | April 2021 | November 2024 | Allow | 43 | 1 | 1 | No | No |
| 17235166 | Platelet-Rich Plasma Compositions and Related Methods | April 2021 | February 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17286073 | METHOD OF ENHANCING ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) | April 2021 | June 2025 | Abandon | 50 | 1 | 1 | No | No |
| 16917701 | HUMAN PLASMA-DERIVED IGG PREPARATION ENRICHED IN ANTI-PARVO B19 NATURAL IGGS | June 2020 | March 2025 | Allow | 56 | 1 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner JADHAO, SAMADHAN JAISING works in Art Unit 1671 and has examined 18 patent applications in our dataset. With an allowance rate of 66.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner JADHAO, SAMADHAN JAISING's allowance rate of 66.7% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by JADHAO, SAMADHAN JAISING receive 0.94 office actions before reaching final disposition. This places the examiner in the 11% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by JADHAO, SAMADHAN JAISING is 43 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +40.0% benefit to allowance rate for applications examined by JADHAO, SAMADHAN JAISING. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 97% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 99% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.